HSE – Medicines Management Programme (MMP)

HSE-MMP Preferred Standard Oral Nutritional Supplements (ONS)

List A: Powdered ONS (Aymes Shake/with Fibre, Aymes Shake Compact, Complan Shake, Ensure Shake, Foodlink Complete/with Fibre, Fresubin Powder Extra) and Compact & Mini Drink sip feeds (Altraplen Compact, Ensure Compact, Fortisip Compact/with Fibre, Fresubin 2Kcal Mini Drink/with Fibre).

HSE-MMP Preferred Blood Glucose Monitoring Devices

The HSE-MMP has identified preferred blood glucose test strips with associated meters for adults with type 1 and type 2 diabetes mellitus. 

In addition, the HSE-MMP has identified preferred continuous glucose monitoring (CGM) sensors with associated systems, for people with diabetes* requiring CGM who are not insulin pump users.

*Reimbursement is supported in accordance with Primary Care Reimbursement Service Circular 033/23.

Prescribing and Cost Guidance: Dry Eye Syndrome

The HSE-MMP has completed a review of the treatment of dry eye syndrome (DES) and published a Prescribing and Cost Guidance document. The guidance document and associated tips and tools recommend first-line preparations based on clinical evidence and cost, and are intended to promote best practice and aid appropriate prescribing for DES.

Managed Access Protocols (MAPs)

Managed Access Protocols are in place for a wide variety of medicines in order to facilitate access for patients. A MAP outlines the criteria that must be satisfied for a patient to be recommended for reimbursement of the medicine.
Examples include

• Community Drug Schemes: bempedoic acid (Nilemdo^®), bempedoic acid plus ezetimibe (Nustendi^®), liraglutide (Saxenda®), rivaroxaban 2.5 mg.
• High Tech Arrangement: medicines for the prophylaxis of episodic and chronic migraine, medicines for moderate-to-severe atopic dermatitis, dupilumab (Dupixent®) for severe asthma, inotersen (Tegsedi®), lanadelumab (Takhzyro®), risdiplam (Evrysdi®), tafamidis (Vyndaqel®), teduglutide (Revestive®), delta-9-tetrahydrocannabinol/cannabidiol (Sativex®), romosozumab (Evenity^®).

Best-Value Biological/Best-Value Medicines

The HSE-Medicines Management Programme has recommended best-value biolocal (BVB)/best-value medicines (BVM) for the following:

• Adalimumab
• Etanercept
• Glatiramer
• Long-acting granulocyte-colony stimulating factors (i.e. lipegfilgrastim, pegfilgrastim)
• Teriparatide